jcm-logo

Journal Browser

Journal Browser

Clinical Advances in Ischemia Reperfusion Injury

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "General Surgery".

Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 4494

Special Issue Editor


E-Mail Website
Guest Editor
Department of General, Visceral and Transplant Surgery, University Hospital Münster, 48149 Münster, Germany
Interests: solid organ transplantation; machine perfusion; innate immune cells; macrophages; resolution of inflammation; ischemia reperfusion injury

Special Issue Information

Dear Colleagues,

Exposure to ischemia and reperfusion is an inherent component of solid-organ transplantation and is axiomatically linked to graft damage. Since organ shortage remains the cardinal issue in transplant medicine, there is an urgent and unmet need to expand the accessible donor pool, especially by utilizing organs from extended-criteria donors. However, these organs are critically affected by ischemia reperfusion injury (IRI). This concern has fostered ongoing experimental and clinical research on IRI in solid-organ transplantation.

Recent landmark studies have demonstrated the potential of hypothermic and normothermic machine perfusion to ameliorate IRI. Moreover, emerging real-time imaging technologies such as hyperspectral imaging promise to more accurately predict the severity of IRI. Additionally, modern organ-preservation solutions are under constant refinement and new therapeutic drugs are in the pipeline to block cellular pathways in IRI. On the other hand, clinical experience in utilizing marginal organs (especially from older donors) continues to grow, which will help to further identify high-risk donors and achieve good clinical outcomes for transplant patients.

For this Special Issue, we welcome authors to submit papers on the clinical advance of IRI in order to discuss recent clinical progress and evolving experimental data.

Dr. Felix Becker
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marginal organs
  • ischemia reperfusion
  • organ transplantation
  • machine perfusion

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

23 pages, 1583 KiB  
Article
The Role of Innate Immune Cells in the Prediction of Early Renal Allograft Injury Following Kidney Transplantation
by Nora Jahn, Ulrich Sack, Sebastian Stehr, Maria Theresa Vöelker, Sven Laudi, Daniel Seehofer, Selim Atay, Panagiota Zgoura, Richard Viebahn, Andreas Boldt and Hans-Michael Hau
J. Clin. Med. 2022, 11(20), 6148; https://doi.org/10.3390/jcm11206148 - 18 Oct 2022
Cited by 4 | Viewed by 1942
Abstract
Background: Despite recent advances and refinements in perioperative management of kidney transplantation (KT), early renal graft injury (eRGI) remains a critical problem with serious impairment of graft function as well as short- and long-term outcome. Serial monitoring of peripheral blood innate immune cells [...] Read more.
Background: Despite recent advances and refinements in perioperative management of kidney transplantation (KT), early renal graft injury (eRGI) remains a critical problem with serious impairment of graft function as well as short- and long-term outcome. Serial monitoring of peripheral blood innate immune cells might be a useful tool in predicting post-transplant eRGI and graft outcome after KT. Methods: In this prospective study, medical data of 50 consecutive patients undergoing KT at the University Hospital of Leipzig were analyzed starting at the day of KT until day 10 after the transplantation. The main outcome parameter was the occurrence of eRGI and other outcome parameters associated with graft function/outcome. eRGI was defined as graft-related complications and clinical signs of renal IRI (ischemia reperfusion injury), such as acute tubular necrosis (ATN), delayed graft function (DGF), initial nonfunction (INF) and graft rejection within 3 months following KT. Typical innate immune cells including neutrophils, natural killer (NK) cells, monocytes, basophils and dendritic cells (myeloid, plasmacytoid) were measured in all patients in peripheral blood at day 0, 1, 3, 7 and 10 after the transplantation. Receiver operating characteristics (ROC) curves were performed to assess their predictive value for eRGI. Cutoff levels were calculated with the Youden index. Significant diagnostic immunological cutoffs and other prognostic clinical factors were tested in a multivariate logistic regression model. Results: Of the 50 included patients, 23 patients developed eRGI. Mean levels of neutrophils and monocytes were significantly higher on most days in the eRGI group compared to the non-eRGI group after transplantation, whereas a significant decrease in NK cell count, basophil levels and DC counts could be found between baseline and postoperative course. ROC analysis indicated that monocytes levels on POD 7 (AUC: 0.91) and NK cell levels on POD 7 (AUC: 0.92) were highly predictive for eRGI after KT. Multivariable analysis identified recipient age (OR 1.53 (95% CI: 1.003–2.350), p = 0.040), recipient body mass index > 25 kg/m2 (OR 5.6 (95% CI: 1.36–23.9), p = 0.015), recipient cardiovascular disease (OR 8.17 (95% CI: 1.28–52.16), p = 0.026), donor age (OR 1.068 (95% CI: 1.011–1.128), p = 0.027), <0.010), deceased-donor transplantation (OR 2.18 (95% CI: 1.091–4.112), p = 0.027) and cold ischemia time (CIT) of the renal graft (OR 1.005 (95% CI: 1.001–1.01), p = 0.019) as clinically relevant prognostic factors associated with increased eRGI following KT. Further, neutrophils > 9.4 × 103/μL on POD 7 (OR 16.1 (95% CI: 1.31–195.6), p = 0.031), monocytes > 1150 cells/ul on POD 7 (OR 7.81 (95% CI: 1.97–63.18), p = 0.048), NK cells < 125 cells/μL on POD 3 (OR 6.97 (95% CI: 3.81–12.7), p < 0.01), basophils < 18.1 cells/μL on POD 10 (OR 3.45 (95% CI: 1.37–12.3), p = 0.02) and mDC < 4.7 cells/μL on POD 7 (OR 11.68 (95% CI: 1.85–73.4), p < 0.01) were revealed as independent biochemical predictive variables for eRGI after KT. Conclusions: We show that the combined measurement of immunological innate variables (NK cells and monocytes on POD 7) and specific clinical factors such as prolonged CIT, increased donor and recipient age and morbidity together with deceased-donor transplantation were significant and specific predictors of eRGI following KT. We suggest that intensified monitoring of these parameters might be a helpful clinical tool in identifying patients at a higher risk of postoperative complication after KT and may therefore help to detect and—by diligent clinical management—even prevent deteriorated outcome due to IRI and eRGI after KT. Full article
(This article belongs to the Special Issue Clinical Advances in Ischemia Reperfusion Injury)
Show Figures

Figure 1

Review

Jump to: Research

16 pages, 1145 KiB  
Review
Innate Immune Cells during Machine Perfusion of Liver Grafts—The Janus Face of Hepatic Macrophages
by Nicola Sariye Roushansarai, Andreas Pascher and Felix Becker
J. Clin. Med. 2022, 11(22), 6669; https://doi.org/10.3390/jcm11226669 - 10 Nov 2022
Cited by 2 | Viewed by 2001
Abstract
Machine perfusion is an emerging technology in the field of liver transplantation. While machine perfusion has now been implemented in clinical routine throughout transplant centers around the world, a debate has arisen regarding its concurrent effect on the complex hepatic immune system during [...] Read more.
Machine perfusion is an emerging technology in the field of liver transplantation. While machine perfusion has now been implemented in clinical routine throughout transplant centers around the world, a debate has arisen regarding its concurrent effect on the complex hepatic immune system during perfusion. Currently, our understanding of the perfusion-elicited processes involving innate immune cells remains incomplete. Hepatic macrophages (Kupffer cells) represent a special subset of hepatic immune cells with a dual pro-inflammatory, as well as a pro-resolving and anti-inflammatory, role in the sequence of ischemia–reperfusion injury. The purpose of this review is to provide an overview of the current data regarding the immunomodulatory role of machine perfusion and to emphasize the importance of macrophages for hepatic ischemia–reperfusion injury. Full article
(This article belongs to the Special Issue Clinical Advances in Ischemia Reperfusion Injury)
Show Figures

Figure 1

Back to TopTop